3-(乙胺基)丙酸 | 10478-41-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-(乙胺基)丙酸
• 英文名称: 3-(ethylamino)propionic acid
• 英文别名: 3-(ethylamino)propanoic acid；3-Ethylaminopropionsaeure；N-ethyl-β-alanine；N-Aethyl-β-alanin；N-monoethyl-β-alanine；3-(Ethylazaniumyl)propanoate
• CAS: 10478-41-8
• 化学式: C₅H₁₁NO₂
• mdl: MFCD06208322
• 分子量: 117.148
• InChiKey: YZPJYHCJKCSXBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(乙胺基)丙酸 在 盐酸 、 三乙胺 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 21.0h， 生成 3-(2,4-Dimethyl-phenyl)-1-ethyl-2-thioxo-tetrahydro-pyrimidin-4-one
  参考文献：
  名称：

  Design, Synthesis, and Biological Evaluation of Thio-Containing Compounds with Serum HDL-Cholesterol-Elevating Properties

  摘要：

  A novel series of substituted sulfanyldihydroimidazolones (1) that modulates high-density lipoprotein cholesterol (HDL-C) has been reported to have HDL-elevating properties in several animal models. Concerns about the chemical and metabolic stability of I directed us to explore the structure-activity relationship (SAR) of a related series of substituted thiohydantoins (2). Expansion of the scope of the thiohydantoin series led to exploration of compounds in related thio-containing ring systems 3-7 and the N-cyanoguanidine derivative 8. Compounds were tested sequentially in three animal models to assess their HDL-C elevating efficacy and safety profiles. Further evaluation of selected compounds in a dose-response paradigm culminated in the identification of compound 2.39 as a candidate compound for advanced preclinical. studies.

  DOI：

  10.1021/jm030219z
• 作为产物：
  描述：

  3-(乙基氨基)丙酸甲酯 在 水 作用下， 生成 3-(乙胺基)丙酸
  参考文献：
  名称：

  某些降压的N-烷基氨基丙酸酯和N，N-二烷基氨基丙酸酯及其异羟肟酸的合成及性质

  摘要：

  报道了选择的3-（N-烷基氨基）-和3-（N，N-二烷基氨基）丙酸酯和异羟肟酸以及一些相关化合物的合成。通过丙烯酸甲酯或甲基丙烯酸甲酯与适当的胺的相互作用制备酯。在某些情况下，酰胺是该反应的副产物，某些受阻胺不会与丙烯酸酯反应。一些酯即使储存很短时间也会水解成相应的羧酸。在羟胺的作用下，由氨基酯制备异羟肟酸。红外，质子磁共振（PMR）和质谱用于表征这些酯，羧酸和异羟肟酸。初步研究了酯，羧酸和异羟肟酸对麻醉猫血压的影响。

  DOI：

  10.1002/jps.2600600103

文献信息

• Bicycloheptane substituted diamide and its congener prostaglandin analogs
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04734424A1

  公开（公告）日：1988-03-29

  Bicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; Q is --CH.dbd.CH--, --CH.sub.2 --, ##STR2## or a single bond; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR3## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, lower alkyl-S-, aryl-S-, arylalkyl-S-, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

  提供了具有结构式##STR1##的双环庚烷取代酰胺前列腺素类似物，其中m为0至4；A为--CH.dbd.CH--或--CH.sub.2 --CH.sub.2 --；n为1至5；Q为--CH.dbd.CH--，--CH.sub.2 --，##STR2##或单键；R为CO.sub.2 H，CO.sub.2烷基，CO.sub.2碱金属，CO.sub.2多羟胺盐，--CH.sub.2 OH，##STR3##其中R.sup.4和R.sup.5相同或不同，为H，低烷基，羟基，低烷氧基或芳基，R.sup.4和R.sup.5中至少有一个不是羟基和低烷氧基；p为1至4；R.sup.1为H或低烷基；q为1至12；R.sup.2为H或低烷基；R.sup.3为H，低烷基，低烯基，低炔基，芳基，芳基烷基，低烷氧基，芳氧基，芳基烷氧基，氨基，烷基氨基，芳基氨基，芳基烷基氨基，低烷基-S-，芳基-S-，芳基烷基-S-，##STR4##（其中n'为0，1或2），烷基氨基烷基，芳基氨基烷基，芳基烷基氨基烷基，烷氧基烷基，芳氧基烷基或芳基烷氧基。这些化合物是心血管药物，例如，在治疗血栓性疾病中有用。
• 7-oxabicycloheptane substituted diamide and its congener prostaglandin
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04663336A1

  公开（公告）日：1987-05-05

  7-Oxabicycloheptane substituted amide prostaglandin analogs are provided having the structural formula ##STR1## wherein m is 0 to 4; A is --CH.dbd.CH-- or --CH.sub.2 --CH.sub.2 --; n is 1 to 5; Q is --CH.dbd.CH--, --CH.sub.2 --, ##STR2## or a single bond; R is CO.sub.2 H, CO.sub.2 alkyl, CO.sub.2 alkali metal, CO.sub.2 polyhydroxyamine salt, --CH.sub.2 OH, ##STR3## wherein R.sup.4 and R.sup.5 are the same or different and are H, lower alkyl, hydroxy, lower alkoxy or aryl, at least one of R.sup.4 and R.sup.5 being other than hydroxy and lower alkoxy; p is 1 to 4; R.sup.1 is H or lower alkyl; q is 1 to 12; R.sup.2 is H or lower alkyl; and R.sup.3 is H, lower alkyl, lower alkenyl, lower alkynyl, aryl, arylalkyl, lower alkoxy, aryloxy, arylalkyloxy, amino, alkylamino arylamino, arylalkylamino, ##STR4## (wherein n' is 0, 1 or 2), alkylaminoalkyl, arylaminoalkyl, arylalkylaminoalkyl, alkoxyalkyl, aryloxyalkyl or arylalkoxyalkyl. The compounds are cardiovascular agents useful, for example, in the treatment of thrombotic disease.

  提供了具有结构式##STR1##的7-氧代双环庚烷取代酰胺前列腺素类似物，其中m为0至4；A为--CH.dbd.CH--或--CH.sub.2 --CH.sub.2 --；n为1至5；Q为--CH.dbd.CH--，--CH.sub.2 --，##STR2##或单键；R为CO.sub.2 H，CO.sub.2烷基，CO.sub.2碱金属，CO.sub.2多羟胺盐，--CH.sub.2 OH，##STR3##其中R.sup.4和R.sup.5相同或不同，为H，低烷基，羟基，低烷氧基或芳基，R.sup.4和R.sup.5中至少有一个不是羟基和低烷氧基；p为1至4；R.sup.1为H或低烷基；q为1至12；R.sup.2为H或低烷基；R.sup.3为H，低烷基，低烯基，低炔基，芳基，芳基烷基，低烷氧基，芳氧基，芳基烷氧基，氨基，烷基氨基，芳基氨基，芳基烷基氨基，##STR4##（其中n'为0，1或2），烷基氨基烷基，芳基氨基烷基，芳基烷基氨基烷基，烷氧基烷基，芳氧基烷基或芳基烷氧基。这些化合物是心血管药物，例如，在治疗血栓性疾病方面有用。
• 2-thioxo-tetrahydropyrimidin-4-one derivatives
  申请人：American Home Products Corporation

  公开号：US05807864A1

  公开（公告）日：1998-09-15

  This invention relates to the use of 2-thioxotetrahydropyrimidin-4-one derivatives to increase HDL cholesterol concentration and as therapeutic compositions for treating atherosclerotic conditions such as dyslipoproteinemias and coronary heart disease. The compounds of this invention are represented by the formula: ##STR1## wherein: R is C.sub.1 -C.sub.6 alkyl, C.sub.2 -C.sub.6 alkenyl, or C.sub.2 -C.sub.6 alkynyl; and R.sup.1, R.sup.2, and R.sup.3 are independently hydrogen, halogen or lower alkyl.

  本发明涉及使用2-硫代四氢嘧啶-4-酮衍生物来增加高密度脂蛋白胆固醇浓度，并作为治疗动脉粥样硬化疾病（如脂蛋白异常和冠心病）的治疗组合物。本发明的化合物由以下公式表示：##STR1## 其中：R为C.sub.1 -C.sub.6烷基，C.sub.2 -C.sub.6烯基或C.sub.2 -C.sub.6炔基；R.sup.1，R.sup.2和R.sup.3独立地为氢、卤素或较低烷基。
• Syntheses and Properties of the Copper(II) Complexes of the Amphoteric Surfactants,<i>N</i>-Alkyl-β-alanine
  作者：Akio Nakamura、Masakatsu Koshinuma、Kazuo Tajima

  DOI：10.1246/bcsj.63.116

  日期：1990.1

  Copper(II) complexes of amphoteric surfactants, N-alkyl-β-alanine (NAA) (the number of carbon atoms in the alkyl chains: n=2, 4, 6, 8, 10, 12), Were synthesized from NAA and copper(II) chloride dihydrate by mixing in aqueous solutions. The properties and structures of these bluish flaky complexes were investigated by elemental analyses, infrared and far-infrared spectroscopy, electronic diffuse reflection spectroscopy, X-ray diffractometry, and thermal analyses. As a result, all of these complexes were found to be composed of one copper(II) ion and two NAA molecules, regardless of the chain length in the alkyl group, (Cu(NAA)2·2H2O), and were also found to have a laminated structure in the crystalline state. A linear relationship was found between the long spacings (d/nm) of the laminated structure and the numbers of carbon atoms (n) in the N-alkyl substituents; d=0.135n+0.62. From these results it was concluded that copper(II) complex molecules have a trans configuration, and are extended and parallel to the normal line of the laminated planes in the crystal. A multiunilayer model for the molecular arrangement of these copper(II) complexes has been proposed, which is quite different from those so far proposed to explain the long spacings observed for metal soap crystals, lyotropic liquid crystal and so on. Also, the role of the alkyl substituents in complex formation has been indicated.

  两性表面活性剂的铜(II)络合物，N-烷基-β-丙氨酸(NAA)（烷基链中的碳原子数：n=2,4,6,8,10,12），由NAA和通过在水溶液中混合而获得二水合氯化铜(II)。通过元素分析、红外和远红外光谱、电子漫反射光谱、X射线衍射和热分析研究了这些蓝色片状配合物的性质和结构。结果发现，所有这些配合物均由一个铜 (II) 离子和两个 NAA 分子组成，无论烷基 (Cu(NAA)2·2H2O) 的链长如何，并且还发现在结晶状态下具有层状结构。层状结构的长间距（d/nm）与N-烷基取代基中的碳原子数（n）之间存在线性关系； d=0.135n+0.62。从这些结果得出结论，铜(II)络合物分子具有反式构型，并且延伸且平行于晶体中层压平面的法线。人们提出了这些铜（II）络合物分子排列的多层模型，该模型与迄今为止提出的解释金属皂晶体、溶致液晶等观察到的长间距的模型有很大不同。此外，还指出了烷基取代基在络合物形成中的作用。
• Effect of the Chain Length of<i>N</i>-Alkyl-β-alanine on Their Copper Complex Formation in Aqueous Solution
  作者：Akio Nakamura、Masakatsu Koshinuma、Kazuo Tajima

  DOI：10.1246/bcsj.63.335

  日期：1990.2

  The effects of the chain length of N-alkyl-β-alanine (NAA) (the number of carbon atoms in the alkyl chains; n=0, 2, 4, 6, 8, 10, 12) on the copper(II) complex formation and its properties were investigated. The complex formation constants for two-step reactions were determined by potentiometry using the selective electrodes of copper(II) and hydrogen ions. The values of the complex formation constants

  N-烷基-β-丙氨酸（NAA）的链长（烷基链中的碳原子数；n=0, 2, 4, 6, 8, 10, 12）对铜（II）的影响络合物的形成及其性质进行了研究。两步反应的络合物形成常数是使用铜 (II) 和氢离子的选择性电极通过电位测定法确定的。配合物形成常数的值随着烷基取代基链长的增加而降低，并且对于长于丁基的取代基变得恒定。这些结果可以用 N-烷基取代基对这些配位反应的位阻效应来解释。发现 1(Cu):2(NAA)-配合物的溶解度和溶度积的每个对数函数分别表示为，作为烷基中碳原子数的线性函数。根据这些数据，从这些成分离子中形成和沉淀 1:2 络合物的标准自由能......